- Home
- Home
- ADME PK
- ADME PK
- In Vitro Metabolism
- In Vitro Metabolism overview
- Reaction Phenotyping
- Cytochrome P450 Induction
- Relative Induction Score
- Cytochrome P450 (CYP) Inhibition (IC50)
- Cytochrome P450 Inhibition (Ki)
- Hepatocyte Stability
- Low Clearance HµREL Co-culture
- Low Clearance Hepatocyte Stability
- Hepatic Uptake Assay
- Metabolite Profiling and Identification
- Plasma Stability
- Microsomal Stability
- Microsomal Binding
- S9 Stability
- Time Dependent CYP Inhibition (single point)
- Time Dependent CYP Inhibition (IC50 shift)
- Time Dependent CYP Inhibition (kinact/KI )
- PXR and AhR Nuclear Receptor Activation
- UGT Inhibition
- In Vitro Permeability and Drug Transporter Services
- In Vitro Permeability and Drug Transporter Services overview
- PAMPA
- Caco-2 Permeability
- MDCK-MDR1 Permeability
- P-gp Substrate Identification
- BCRP Substrate Identification
- Human SLC Transporter Substrate Identification
- Human MRP Transporter Substrate Identification
- Preclinical Hepatic Oatp Substrate Identification
- P-glycoprotein Inhibition Service
- BCRP Inhibition Service
- Human SLC Transporter Inhibition
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Preclinical Hepatic Oatp Transporter Inhibition
- Non-CYP Mediated Metabolism
- Protein Binding
- Bioanalysis
- High Throughput ADME
- DDI Packages
- Prodrug Services
- Toxicology
- Toxicology
- Multiparametric Toxicity
- Immunotoxicology
- Mitochondrial Toxicity
- 3D Microtissue Models
- Hepatotoxicity and Drug-induced Liver Injury (DILI)
- Hepatotoxicity and Drug-induced Liver Injury (DILI) overview
- CellCiphr® Premier
- Cytotoxicity Screening Panel
- Drug Induced Phospholipidosis & Steatosis Assay
- Lysosomal Trapping
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Reactive Metabolite Assessment
- Cytochrome P450 Time Dependent Inhibition (IC50 Shift)
- Mitochondrial Toxicity
- Transcriptomics Services
- Genotoxicity
- 3D Hepatotoxicity Assay using HepaRG Spheroids
- Mechanistic Toxicity
- Mechanistic Toxicity overview
- Apoptosis and Necrosis Assay (Flow Cytometry)
- Cell Stress Panel
- Phospholipidosis and Steatosis
- Lysosomal Trapping
- Hemolysis
- DILIsym collaboration
- Reactive Metabolite
- Toxicological Gene Regulation
- Cell Viability
- KeratinoSensâ„¢ Skin Sensitization
- Androgen Receptor Modulation
- Phototoxicity
- Genotoxicity
- Neurotoxicity
- Cardiotoxicity
- Nephrotoxicity
- Drug-Drug Interactions
- Non-GLP Exploratory Toxicology
- Customized Toxicology Service
- In Silico
- Physicochemical Profiling
- About
- Services
- Services
- ADME PK
- ADME PK
- In Vitro Metabolism
- In Vitro Metabolism overview
- Reaction Phenotyping
- Cytochrome P450 Induction
- Relative Induction Score
- Cytochrome P450 (CYP) Inhibition (IC50)
- Cytochrome P450 Inhibition (Ki)
- Hepatocyte Stability
- Low Clearance HµREL Co-culture
- Low Clearance Hepatocyte Stability
- Hepatic Uptake Assay
- Metabolite Profiling and Identification
- Plasma Stability
- Microsomal Stability
- Microsomal Binding
- S9 Stability
- Time Dependent CYP Inhibition (single point)
- Time Dependent CYP Inhibition (IC50 shift)
- Time Dependent CYP Inhibition (kinact/KI )
- PXR and AhR Nuclear Receptor Activation
- UGT Inhibition
- In Vitro Permeability and Drug Transporter Services
- In Vitro Permeability and Drug Transporter Services overview
- PAMPA
- Caco-2 Permeability
- MDCK-MDR1 Permeability
- P-gp Substrate Identification
- BCRP Substrate Identification
- Human SLC Transporter Substrate Identification
- Human MRP Transporter Substrate Identification
- Preclinical Hepatic Oatp Substrate Identification
- P-glycoprotein Inhibition Service
- BCRP Inhibition Service
- Human SLC Transporter Inhibition
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Preclinical Hepatic Oatp Transporter Inhibition
- Non-CYP Mediated Metabolism
- Protein Binding
- Bioanalysis
- High Throughput ADME
- DDI Packages
- Prodrug Services
- Toxicology
- Toxicology
- Multiparametric Toxicity
- Immunotoxicology
- Mitochondrial Toxicity
- 3D Microtissue Models
- Hepatotoxicity and Drug-induced Liver Injury (DILI)
- Hepatotoxicity and Drug-induced Liver Injury (DILI) overview
- CellCiphr® Premier
- Cytotoxicity Screening Panel
- Drug Induced Phospholipidosis & Steatosis Assay
- Lysosomal Trapping
- BSEP, MRP2, MRP3 and MRP4 Inhibition
- Reactive Metabolite Assessment
- Cytochrome P450 Time Dependent Inhibition (IC50 Shift)
- Mitochondrial Toxicity
- Transcriptomics Services
- Genotoxicity
- 3D Hepatotoxicity Assay using HepaRG Spheroids
- Mechanistic Toxicity
- Mechanistic Toxicity overview
- Apoptosis and Necrosis Assay (Flow Cytometry)
- Cell Stress Panel
- Phospholipidosis and Steatosis
- Lysosomal Trapping
- Hemolysis
- DILIsym collaboration
- Reactive Metabolite
- Toxicological Gene Regulation
- Cell Viability
- KeratinoSensâ„¢ Skin Sensitization
- Androgen Receptor Modulation
- Phototoxicity
- Genotoxicity
- Neurotoxicity
- Cardiotoxicity
- Nephrotoxicity
- Drug-Drug Interactions
- Non-GLP Exploratory Toxicology
- Customized Toxicology Service
- In Silico
- Physicochemical Profiling
- Unique Technologies
- Guides
- Events
- News
- Investor
- Careers
- Contact
Home > Investor
Cyprotex was acquired by Evotec AG in December 2016. The Investor Relations section has now been removed from the Cyprotex website. Please refer to the Evotec website for future Investor Relations updates.
Close
Contact us to discuss your ADME Tox issues or request a quote
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
info@evotec.eu
or fill out the form below:
Close
Close
Download file
Close